IL5 and asthma: Another anti-IL5 mAb (IgG4/k) Reslizumab, showed similar reduction in sputum eosinophils, significant improvement in lung function (P= 0.002, vs. placebo) and a trend towards improved asthma scores (P= 0.054, vs. placebo) in patients diagnosed with severe refractory eosinophilic asthma (see Table 1).